Måndag 13 Januari | 19:15:56 Europe / Stockholm
Svenska | English

Carnegie Access

Prenumeration

Guard Therapeutics: 25% of patients included in the Phase IIb POINTER trial
2025-01-09 17:23:00

Carnegie has published a new commissioned research report on Guard Therapeutics.

To access the full report and subscribe to future updates, visit https://www.carnegie.se/en/commissioned-research/guardtherapeutics/

Information
This is a press release from Carnegie. For information about Carnegie commissioned research, see https://www.carnegie.se/en/commissioned-research/, or contact our commissioned research team at cr@carnegie.se.

Contacts
Visiting address: Regeringsgatan 56, Stockholm
Site: http://www.carnegie.se
Telephone: +46 8-5886 88 00

About Us
Carnegie is the leading and independent Nordic investment and private bank. Our operations within Corporate Finance, Securities and Research, Private Banking and Wealth Management are among the market leaders within their respective sectors. Together, they build an unbeatable combination of integrated knowledge, guiding our clients towards better business. Carnegie operates in six countries and has more than 800 employees.

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden